JP2022527858A5 - - Google Patents

Info

Publication number
JP2022527858A5
JP2022527858A5 JP2021560300A JP2021560300A JP2022527858A5 JP 2022527858 A5 JP2022527858 A5 JP 2022527858A5 JP 2021560300 A JP2021560300 A JP 2021560300A JP 2021560300 A JP2021560300 A JP 2021560300A JP 2022527858 A5 JP2022527858 A5 JP 2022527858A5
Authority
JP
Japan
Prior art keywords
cancer
delivery system
drug delivery
use according
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560300A
Other languages
English (en)
Japanese (ja)
Other versions
JP7550167B2 (ja
JP2022527858A (ja
Filing date
Publication date
Priority claimed from US16/366,596 external-priority patent/US11806330B2/en
Application filed filed Critical
Publication of JP2022527858A publication Critical patent/JP2022527858A/ja
Publication of JP2022527858A5 publication Critical patent/JP2022527858A5/ja
Application granted granted Critical
Publication of JP7550167B2 publication Critical patent/JP7550167B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560300A 2018-03-27 2019-09-26 がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子 Active JP7550167B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
NO20180429 2018-03-27
US16/366,596 2019-03-27
US16/366,596 US11806330B2 (en) 2018-03-27 2019-03-27 PACA and cabazitaxel for anti-cancer treatment
PCT/EP2019/076121 WO2020192950A1 (en) 2018-03-27 2019-09-26 Poly (alkyl cyanoacrylate) nanoparticles for use in treatment of cancer

Publications (3)

Publication Number Publication Date
JP2022527858A JP2022527858A (ja) 2022-06-06
JP2022527858A5 true JP2022527858A5 (cg-RX-API-DMAC7.html) 2022-10-03
JP7550167B2 JP7550167B2 (ja) 2024-09-12

Family

ID=66049182

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020552260A Active JP7317038B2 (ja) 2018-03-27 2019-03-27 がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子
JP2021560300A Active JP7550167B2 (ja) 2018-03-27 2019-09-26 がんの治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020552260A Active JP7317038B2 (ja) 2018-03-27 2019-03-27 がん治療に使用するためのポリ(アルキルシアノアクリレート)ナノ粒子

Country Status (8)

Country Link
US (3) US20210113482A1 (cg-RX-API-DMAC7.html)
EP (2) EP3773471A1 (cg-RX-API-DMAC7.html)
JP (2) JP7317038B2 (cg-RX-API-DMAC7.html)
CN (2) CN111989087A (cg-RX-API-DMAC7.html)
AU (1) AU2019437385B2 (cg-RX-API-DMAC7.html)
BR (2) BR112020019452A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134923A1 (cg-RX-API-DMAC7.html)
WO (2) WO2019185685A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer
CN111989087A (zh) 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
JP7461932B2 (ja) * 2018-08-23 2024-04-04 シンテフ ティーティーオー エイエス ナノ粒子
KR20230031188A (ko) * 2020-02-26 2023-03-07 바이오써젠 에이에스 치료적 폴리엔 마크롤리드의 제약 조성물 및 그의 사용 방법
GB202501169D0 (en) 2025-01-27 2025-03-12 Sintef Tto As Methods of producing polymeric particles

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2872703B1 (fr) 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
JP2008542293A (ja) 2005-05-23 2008-11-27 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 超音波増強ナノ粒子媒介性薬物送達のためのエコー形成性マイクロバブルおよびマイクロエマルジョン
EP1876188A1 (en) 2006-07-04 2008-01-09 NanoDel Technologies GmbH Two step miniemulsion process
US8679539B2 (en) * 2007-01-31 2014-03-25 Tong Shen Enterprise Co., Ltd. Drug-loaded poly (alkyl-cyanoacrylate) nanoparticles and process for the preparation thereof
FR2921660B1 (fr) 2007-10-01 2015-09-25 Centre Nat Rech Scient Nanoparticules hybrides organiques inorganiques a base de carboxylates de fer.
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
ES2424476T3 (es) 2011-03-31 2013-10-02 Bioalliance Pharma Nanopartículas cargadas con fármaco antitumoral quimioterápico
US20150343079A1 (en) 2012-10-25 2015-12-03 Sogang University Research Foundation Ultrasound contrast agent with nanoparticles including drug and method for preparing the same
EP3004183B1 (en) 2013-05-28 2017-07-05 Sintef TTO AS Process for preparing stealth nanoparticles
US10391185B2 (en) 2014-11-26 2019-08-27 Fujifilm Visualsonics, Inc. Multimodal ultrasound and photoacoustic contrast agent based on polymeric microparticles
WO2016134115A1 (en) 2015-02-20 2016-08-25 Trustees Of Boston University Theranostic compositions and uses thereof
EP3316871A4 (en) * 2015-06-30 2019-02-20 The Trustees of Columbia University in the City of New York TALKED COMPOSITION AND USES THEREOF
US20170071866A1 (en) * 2015-09-14 2017-03-16 Onxeo S.A. Nanoparticles loaded with active ingredients, their process of preparation, and their uses
WO2017046037A1 (en) * 2015-09-14 2017-03-23 Onxeo Nanoparticles loaded with active ingredients, their process of preparation and their uses
US10980826B2 (en) * 2015-11-06 2021-04-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR102803158B1 (ko) * 2015-12-02 2025-05-08 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
WO2017143967A1 (zh) 2016-02-24 2017-08-31 首都医科大学宣武医院 一种双重修饰聚氰基丙烯酸正丁酯纳米粒、其制备方法及用途
KR20170133257A (ko) 2016-05-24 2017-12-05 한양대학교 산학협력단 항암제 함유 나노입자를 포함하는 뇌질환 치료를 위한 비강 투여용 약제학적 조성물
EP3518900A1 (en) 2016-09-29 2019-08-07 Sintef TTO AS A new drug delivery system for treatment of disease
NO342271B1 (en) 2016-09-29 2018-04-30 Sintef Tto As A new drug delivery system for treatment of cancer
CN111989087A (zh) * 2018-03-27 2020-11-24 新泰福托特股份有限公司 用于治疗癌症的聚(氰基丙烯酸烷基酯)纳米颗粒
US12433846B2 (en) 2019-03-27 2025-10-07 Sintef Tto As Drug delivery system for treatment of cancer

Similar Documents

Publication Publication Date Title
Sun et al. Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy
Xiong et al. Tumor immune microenvironment and nano-immunotherapeutics in colorectal cancer
Shan et al. Emerging prodrug-engineered nanomedicines for synergistic chemo-phototherapy
Gulbake et al. Insight to drug delivery aspects for colorectal cancer
Javan et al. Development of a magnetic nanostructure for co-delivery of metformin and silibinin on growth of lung cancer cells: possible action through leptin gene and its receptor regulation
Hu et al. The application of nanoparticles in immunotherapy for hepatocellular carcinoma
Wang et al. Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: a review
JP2014531456A5 (cg-RX-API-DMAC7.html)
Kuriakose et al. Potential therapeutic strategies for hypertension‐exacerbated cardiotoxicity of anticancer drugs
RU2019133284A (ru) Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства
JP2017501155A5 (cg-RX-API-DMAC7.html)
RU2012107535A (ru) КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
Chen et al. Tumor cell-derived microparticles packaging monocarboxylate transporter4 inhibitor fluvastatin suppress lung adenocarcinoma via tumor microenvironment remodeling and improve chemotherapy
JP2023096009A5 (cg-RX-API-DMAC7.html)
Hassanzadeganroudsari et al. Enhancing anti-cancer efficacy of carboplatin by PEGylated poly (butyl cyanoacrylate) nano-particles
MX2023007436A (es) Arn terapeutico para tratar cancer.
Zhang et al. Targeted delivery of dasatinib to deplete tumor-associated macrophages by mannosylated mixed micelles for tumor immunotherapy
Xu et al. Recent advances in the treatment of colon cancer
Wei et al. Cell-and subcellular organelle-targeting nanoparticle-mediated breast cancer therapy
Tamura et al. Improving adenoviral vectors and strategies for prostate cancer gene therapy
Wande et al. Modified chitosan nanogel-polymersomes for oral co-delivery of oxaliplatin and rapamycin for synergistic chemotherapy
Mohammadi et al. The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential
Qu et al. Cyclodextrins as non-viral vectors in cancer theranostics: A review
Nteli et al. Nanomedicine approaches for treatment of hematologic and oncologic malignancies
Hatami et al. In vitro co-delivery evaluation of PEGylated nano-liposome loaded by glycyrrhizic acid and cisplatin on cancer cell lines